(CercleFinance.com) – Novo Nordisk announced on Wednesday the signing of a partnership with the Canadian Aspect Biosystems providing for the granting of a license option on a technology for printing human tissues.
The Danish laboratory explains that the objective of the agreement is to use bio-printing from stem cells in order to maintain normal blood sugar levels without resorting to immunosuppression.
From Novo’s point of view, this could be a real ‘upheaval’ in the management of patients with type 1 diabetes.
Under the terms of the agreement, the pharmaceutical company will benefit from exclusive rights to Aspect’s technology, with the possibility of developing up to four potential treatments for diabetes and/or obesity.
In return, Aspect will receive an initial payment of $75 million, to which an additional $650 million could be added in the form of milestone payments depending on the commercial and regulatory progress of the projects, not including any royalties related to the commercialization of the treatments. likely to emerge.
On the Copenhagen Stock Exchange, Novo Nordisk shares rose 1.2% in the wake of this information, compared with a gain of 0.1% for the Danish market as a whole.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
